Theriva Biologics, Inc.
TOVX
$0.21
-$0.01-5.94%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.37M | 15.83M | 6.39M | 6.70M | 6.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.73M | 26.37M | 17.94M | 18.73M | 20.21M |
| Operating Income | -25.73M | -26.37M | -17.94M | -18.73M | -20.21M |
| Income Before Tax | -26.19M | -29.56M | -24.81M | -25.65M | -27.12M |
| Income Tax Expenses | -- | -- | -- | -- | -424.00K |
| Earnings from Continuing Operations | -26.19 | -29.56 | -24.81 | -25.65 | -26.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.19M | -29.56M | -24.81M | -25.65M | -26.69M |
| EBIT | -25.73M | -26.37M | -17.94M | -18.73M | -20.21M |
| EBITDA | -25.62M | -26.26M | -17.81M | -18.59M | -20.06M |
| EPS Basic | -5.53 | -11.89 | -20.68 | -26.65 | -33.09 |
| Normalized Basic EPS | -3.37 | -5.49 | -7.93 | -11.48 | -15.63 |
| EPS Diluted | -5.53 | -11.89 | -20.68 | -26.65 | -33.09 |
| Normalized Diluted EPS | -3.37 | -5.49 | -7.93 | -11.48 | -15.63 |
| Average Basic Shares Outstanding | 22.00M | 13.46M | 7.49M | 5.39M | 3.28M |
| Average Diluted Shares Outstanding | 22.00M | 13.46M | 7.49M | 5.39M | 3.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |